<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870620</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_MBC-Registry</org_study_id>
    <nct_id>NCT03870620</nct_id>
  </id_info>
  <brief_title>Metastatic Breast Cancer in Austria</brief_title>
  <official_title>Metastatic Breast Cancer in Austria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the most common cancer among women worldwide. In Austria, this diagnosis is&#xD;
      made more than 5000 times a year (STATISTICS AUSTRIA, Austrian Cancer Registry, as of&#xD;
      24.09.2012). Of these, already 5% to 10% have distant metastases at the time of initial&#xD;
      diagnosis, and up to 30% of the node-negative tumours and up to 70% of the node-positive&#xD;
      tumours metastasise at a later date. Metastatic breast cancer has not been systematically&#xD;
      assessed in Austria to date. This medical registry of the AGMT is thus the first&#xD;
      Austrian-wide standardised documentation of this disease. The aim of the registry is to&#xD;
      answer both epidemiological and therapy-specific questions.&#xD;
&#xD;
      This registry is a prospective and retrospective, multicentre collection of data on patients&#xD;
      with metastatic breast cancer in Austria. All tumour characteristics, medical histories and&#xD;
      also treatment sequences are documented in anonymised form.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present AGMT registry will provide accurate documentation of initial disease progression&#xD;
      and initial tumour characteristics in patients with metastatic breast cancer in Austria. The&#xD;
      data collected will include: median age at metastasis, median disease-free survival (DFS)&#xD;
      between initial diagnosis or first date of absence of disease and occurrence of metastasis,&#xD;
      histological subtype of the primary tumour, initial TNM stage, grade and receptor status of&#xD;
      the primary tumour, type and form of adjuvant therapy, pattern of metastasis and metastasis&#xD;
      site. Characteristics that have a negative prognostic value are expected to be&#xD;
      overrepresented in the metastatic patient group.&#xD;
&#xD;
      Also, this AGMT registry is intended to assess the distribution pattern of these metastatic&#xD;
      stage subtypes in Austria. Additionally, their influence on treatment strategy and outcome is&#xD;
      to be studied. Furthermore, the frequency and tumour characteristics of breast cancer in male&#xD;
      patients will be assessed and the influence of gender on treatment strategies identified.&#xD;
&#xD;
      The AGMT breast cancer registry will conduct an exact analysis of survival data, thereby&#xD;
      enabling accurate calculations of average survival duration in patients with metastatic&#xD;
      breast cancer in Austria. Further parameters that reflect the quality or course of&#xD;
      oncological treatment are the survival rates from the time of metastasis development at 1, 2&#xD;
      and 5 years after diagnosis.&#xD;
&#xD;
      This AGMT registry is intended to investigate the response to various therapies in a real&#xD;
      life population in relation to previous treatments, concomitant diseases and breast cancer&#xD;
      subtype. The aim is to assess which therapies are used at which time point and on which&#xD;
      disease subtype they depend.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2015</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with prognostic factors for metastatic breast cancer</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients according to molecular subtypes</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and tumour characteristics of breast cancer in male patients</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival of patients with metastatic breast cancer in Austria</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Carcinoma</condition>
  <condition>Breast Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This registry is a prospective and retrospective, multicentre collection of data on&#xD;
        patients with metastatic breast cancer in Austria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological evidence of breast cancer&#xD;
&#xD;
          -  Histological and/or radiological evidence of metastases&#xD;
&#xD;
          -  Metastasis within 10 years of registry initiation&#xD;
&#xD;
          -  Signed informed consent (if a patient has already died at the time of entry, the entry&#xD;
             can be made without a declaration of consent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Due to the non-interventional design of the registry there are no specific exclusion&#xD;
             criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Greil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IIIrd Medical Department, Private Medical University Hospital Salzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Greil, MD</last_name>
    <phone>+43 57255</phone>
    <phone_ext>25801</phone_ext>
    <email>r.greil@salk.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>BHS Linz</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Steyr</name>
      <address>
        <city>Steyr</city>
        <state>Oberösterreich</state>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels Grieskirchen</name>
      <address>
        <city>Wels</city>
        <state>Oberösterreich</state>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH-Univ. Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Frauenheilkunde Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BKH Kufstein</name>
      <address>
        <city>Kufstein</city>
        <state>Tirol</state>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin III Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AKH Wien, Universitätsklinik für Frauenheilkunde</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

